Afinitor 2015 U.S. PROMOTIONAL AUDIT REPORT

Published July 2016 • 31 Pages

The 5 Key Questions Addressed by this Report:

• How many physicians were reached by Afinitor through personal promotion in 2015 and how does this compare to its peer set in the Astrocytoma, Breast Cancer, pNET, and Renal Cancer markets?
• What promotional mix was leveraged (e.g., sales rep detailing, physician education, and paid speaking) and what was the median spend on each type of activity?
• How does Novartis’s depth of coverage vary within key specialties (e.g., Hematology/Oncology, Medical Oncology, Neurology, Internal Medicine, Urology, Radiation Oncology, and Nephrology) and how does this compare to its peers and the overall set of rep-accessible physicians?
• How often are physicians receiving paid meals for Afinitor throughout the year (e.g., monthly, quarterly, annually)?
• Who were the most detailed prescribers and top paid speakers/consultants for Afinitor in 2015?

Data Sources and Methodology:

• MDDetails leverages company-reported financial transaction data disclosed through CMS Open Payments. This data set captures all transfers of value (e.g., speaking fees, consulting fees, travel, education, and meals) made on behalf of a drug or device manufacturer to a physician. Currently, 30 months of longitudinal data is available – covering payments to more than 800,000 U.S. healthcare professionals.
• Over 19,200 paid interactions across 6,000 physicians made on behalf of Afinitor were carefully examined to support our analysis. In addition, interaction data from 16 peer products (e.g. Abraxane, Avastin, Fareston, Faslodex, Halaven, Herceptin, Ibrance, Inlyta, Kadcyla, Nexavar, Opdivo, Perjeta, Proleukin, Sutent, Torisel, and Votrient) was leveraged to provide benchmarking and market insights.